Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy.
Pietro Emiliano DonedduDario CocitoFiore ManganelliRaffaella FazioChiara BrianiMassimiliano MirabellaLuana BenedettiElisa BianchiStefano JannAnna MazzeoGiovanni AntoniniGiuseppe CosentinoGirolama Alessandra MarfiaAndrea CorteseAngelo Maurizio ClericiMarinella CarpoAngelo SchenoneGabriele SicilianoMarco LuigettiGiuseppe Lauria PinterTiziana RossoGuido CavalettiEttore BeghiGiuseppe LiberatoreLucio SantoroEmanuele SpinaErdita PeciStefano TronciMarta RuizStefano Cotti PiccinelliElena Pinuccia VerrengiaLuca GentileLuca LeonardiGiorgia MataluniLaura PiccoloEduardo Nobile-Orazionull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2020)
Comorbidities are frequent in patients with CIDP and in almost 50% of them have an impact on treatment choice. Diabetes, MGUS and other immune diseases are more frequent in patients with CIDP than in the general population. Only diabetes seems, however, to have an impact on disease severity and treatment response possibly reflecting in some patients a coexisting diabetic neuropathy.